2026/06/06
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form
BEIJING, China May 29, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it re
2026/05/30
May 27, 2026 — SINOVAC has received approval from the National Medical Products Administration (NMPA) to launch clinical trials for its Influenza Vaccine (Split Virion), Inactivated (MDCK cell). The P
2026/05/27
BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has extended the dead
2026/05/21
The content is intended for use by media professionals
These images may be downloaded for non-commercial use and for purposes such as news reporting or research. Images may not be modified and must display the following copyright language: Copyright © SINOVAC Biotech Ltd. All rights reserved.
Learn more about SINOVAC copyright and trademark policies.
Media Contacts: pr@sinovac.com
EN
